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1. Introduction 
Depression is a common underdiagnosed, undertreated and costly mood disorder 
associated with substantial morbidity and mortality (1-3). It is related to the emotion of 
sadness or irritability and accompanied by several psycophysiological changes, such as 
disturbances in sleep, appetite or sexual desire; constipation; loss of the ability to experience 
pleasure in work or with friends; crying; suicidal thoughts; and slowing of speech and 
action (4-6). Approximately 5% of the population has major depression at any given time, 
with men experiencing a lifetime risk of 7%-12%; and women 20%-25% (3, 5). 
Depressive mood is one of the most common – and potentially dangerous – psychiatric 
complications of every chronic disease because it often worsens the overall clinical 
condition. The prevalence of depression in patients with chronic conditions ranges from 
25 to 33 percent and is frequent among people hospitalized with cancer, who have had a 
recent heart attack or stroke, or have diabetes or Parkinson’s disease (7). Besides, even 
between non-hospitalized patients, depression has an important effect on life and may 
limit the social activities of individuals. People who are depressed tend to be more 
withdrawn from their community, friends and family, are less likely to work, present a 
decreased productivity and retire earlier. The relevant social-economic and clinical 
impacts of mood disorder, especially depression, on patient’s life have drawn attention to 
possible therapeutic mechanisms that could improve the quality of life and outcomes of 
depressive patients. 
The clinical approach of patients suffering of depressive mood has evolved considerably 
throughout years and includes mainly supportive care combined with pharmacotherapy 
and psychotherapy (8, 9). Globally, treatment planning requires coordination of short-term 
strategies to induce remission associated with longer term maintenance designed to prevent 
recurrence. The wide variety of drugs available to treat depressive patients has given the 
physician a large spectrum of therapeutic possibilities for a rationale approach. 
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Approximately 35 million adults in Unite States population, at least once in lifetime, 
experience an episode of major depression (3). The essential feature of a major depressive 
event is defined as a persistent period of at least two weeks in which there is either 
depressive mood or the loss of interest or pleasure in nearly all activities (DSM-IV). The 
available treatment currently used includes selective serotonin reuptake inhibitors (SSRI), 
tricyclic antidepressants (TCA), selective norepinephrine reuptake inhibitors (NRI) and 
monoamine oxidase inhibitors (MAOI). However, only 47% of patients respond well to 
antidepressant treatment and only 33% of patients achieve remission in the first line of 
treatment with a widely used selective serotonin reuptake inhibitors (10). Additionally, 
relapse within 6-12 months is verified in approximately 50% of those who remit (11). 
Therefore, while currently available treatments are amongst the most widely prescribed 
drugs, they fail to have an effect on many patients and have incomplete effects for many 
others. Treatment-resistant depression has an estimated prevalence of 2-5% and continued 
depressive symptoms are directly responsible to ongoing functional impairment, 
increased utilization of health care resources, a high risk of suicide and an overall 
increased mortality (12-14). An effective treatment is then necessary, but there is very 
limited evidence for the efficacy of any specific therapeutic intervention in chronic, 
treatment-refractory depression. 
Electroconvulsive therapy (ECT) is the main procedure indicated to patients resistant to 
antidepressive medications and consists of the induction of convulsive crises by means of 
applying an electric current through the brain for therapeutic purpose (15). The remission 
rate is of depression with electroconvulsive therapy varies, generally, from 50% to 80% (15). 
However, ECT may have important side effects, especially cognitive impairment, that can 
limit its clinical use (16) and it is associated with a high relapse rate (15, 17). 
Repetitive transcranial magnetic stimulation (rTMS) was recently approved by FDA (Food 
and Drug Administration) for the treatment of depression that has not responded to one 
antidepressant medication. This procedure is well-tolerated and has few side effects. Its 
mechanism of therapeutic action is linked to the principal of electromagnetic induction 
discovered by Faraday in 1831 by wich electrical energy and magnetic fields are related. 
According to Pascual-Leone, an increased neuronal excitability linked to the increase of 
magnetic field may produce electrical currents in certain areas of the brain, especially the 
left prefrontal cortex, and reduce the depressive symptoms (18). rTMS has been described as 
a generally safe technique with consistent statistically significant antidepressant results (19, 
20), however is associated with relatively low response rate and the maintenance of benefits 
over time is relatively unknown (21). 
Vagus nerve stimulation (VNS) was approved in 2005 for the treatment of patients failing to 
respond to, at least, four antidepressant drugs and refers to electrical stimulation of the 
cervical portion of the left vagus nerve through a surgically implanted electrode and pulse 
generator. Surgical risks are relatively minor and long-term treatment is usually well 
tolerated. However, it has been noted that only a substantial minority of patients with 
extremely difficult-to-treat depressive disorder benefit from VNS and 21%-50% of patients 
who responded to VNS failed to maintain at least a 40% decrease in baseline depression 
severity over 1-2 years (22-24). 
Deep brain stimulation (DBS) has been described as a promising therapy to severe and 
treatment-resistant depression. Since 2005, when Mayberg and colleagues (25) have 
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reported that the subgenual cingulated region (Brodman area 25) is a potential target to 
electrical stimulation with effective reverse of symptoms in patients suffering treatment-
resistant depression, a large number of studies have been conduced to explore other 
potential sites in the brain that could be involved on the mechanisms of depressive mood 
disorders.  
This procedure is characterized by a stereotactical implantation of an intracranial 
electrode that is connected to a pulse generator/battery pack (26). In 1947, at Temple 
University in Philadelphia, the neurologist Spiegel and the neurosurgeon Wycis first 
described a stereotactic apparatus and its use in humans to perform ablative procedures 
(27). The great knowledge achieved from the treatment of patients with movement 
disorders with DBS, such as Parkinson’s disease, primary dystonia, and essential tremor, 
allowed its experimental use also on patients with treatment-resistant depression with 
encouraging results. Due to its reversible, revisable and adjustable potential, DBS 
represents an alternative and additional therapeutic approach to treatment-resistant 
depression. 
The initial evidence that a focal disrupting pathological activity in limbic-cortical pathways 
was present in patients with negative mood was observed by Mayberg and colleagues, in 
1999 (28). Using functional neuroimaging studies, they consistently demonstrated the 
involvement of the subgenual cingulate (Cg25) (Brodmann area 25) in both the acute 
sadness and antidepressant treatment effects. A markedly increased blood flow was noted 
to the Cg25 during induction of transient normal sadness and, in contrast, a decreased 
activity was reported with clinical response to different antidepressant treatments, which 
suggested a critical role for this region in modulating negative mood states. This scientific 
observation raised the hypothesis that a therapeutic intervention on specific sites of the 
limbic-cortical circuits could effectively reverse the symptoms of otherwise treatment-
resistant depression. Mayberg and colleagues, in 2005 (29), on an open-label study, applied 
bilateral DBS on the subcallosal cingulate white matter in six patients with treatment-
resistant depression and observed a clinically significant antidepressant response in four 
after 6 months, which is known as the first published report of DBS for treatment-resistant 
depression. 
Based on the presence of neuronal dysregulation in limbic-cortical circuits and positive 
lesional effects, various target areas for depressive disorders have been discussed. 
Schlaepfer and colleagues, in 2008 (30), stimulating the nucleus accumbens of 3 patients, 
observed after one week, 42% reduction in symptoms. Malone and colleagues, in 2009 (31), 
stimulating the ventral internal capsule and ventral striatum of 15 patients, noted a distinct 
reduction in symptoms by 57% during 12 months. Lozano and colleagues, in 2008 (32), 
stimulating the subgenual area of cingulum of 20 patients, observed reduction in symptoms 
by an average 48% during 12 months, with 2 non-responders and 7 remission. Other targets 
for DBS in treatment resistant depression have been proposed, including globus pallidus 
internus, inferior thalamic peduncle, lateral habenula and the rostral cingulated cortex (33, 
34) (Table 1).  
The ideal patient that may benefit from DBS is still a matter of controversy. The failure to 
two antidepressant treatments in the current episode appears to have a predictive validity. 
In STAR*D, remission rates in successive stages of treatment were 36.8% in the first 
treatment, 30.6% in the second treatment, 13.7% in the third treatment, and 13.0% in  
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2005 Mayberg et al (28) Canada 6 Subgenual area of 
cingulum 
71% 
2008 Schlaepfer et al (29) Germany 3 Nucleus 
accumbens 
42% 
2008 Lozano et al (31) Canada 20 Subgenual area of 
cingulum 
48% 




2011 Puigdemont et al 
(35) 
Spain 8 Subgenual area of 
cingulum 
50% 
2011 Kennedy et al (36) Canada 20 Subcallosal 
cingulate gyrus 
64.3% 
Table 1. deep brain stimulation in patients presenting treatment-resistant depression. 
the forth treatment (11). Additionally, the likelihood of remission is markedly lower for 
patients for whom two or more adequate antidepressant trials failed (11). Therefore, in 
some studies, to qualify for DBS, patients had to be in an episode of major depression for 
at least 1 year and had to have failed to respond to at least four treatments (32). Exclusion 
criteria usually includes substance abuse, severe personality disorder and psychotic 
depression (35). 
The potential for adverse effects from DBS for treatment-resistant depression has not been 
completely studied. Lozano and colleagues, in 2008 (32), reported increased depression in 
10% of patients that underwent DBS of the subgenual area of cingulum. Moreover, Malone 
and colleagues, in 2009 (31), describe hippomanic episodes, increased suicidility and 
syncope on patients submitted to DBS of internal capsule/ventral striatum. Future studies 
must carefully point the most commons adverse effects and complications, and the specific 
targets related to it as well.  
DBS is a recently proposed therapeutic approach to treatment-resistant depression and, 
therefore, remains with many unsolved questions. Future investigations must correctly 
address which patient benefits most from the surgical procedure and which is the best 
therapeutic target or, if not possible, which target best correlates to specific symptoms of 
depression. Large, randomized placebo-controlled studies of DBS for treatment-resistant are 
necessary to describe the potential risks and complications from operation. Additionally, as 
the study of DBS progresses, complementary information must put into evidence which is 
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the best adjunctive therapy, the potential interactions of pharmacotherapy and the relative 
safety and efficacy of the various DBS targets. 
This review aimed to describe the context in which DBS has emerged as an experimental 
therapy for refractory depression, present a brief historical note, discuss the different targets 
in these pathological neuro-psychiatric disorder, review the preliminary results of some 
clinical studies, and discuss the pros and cons of the method, as well as the possible adverse 
effects and future perspectives. 
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